Bloomberg Television
@markets·3.2M subscribers·95.6K videos
Novo Nordisk Selloff Is an Overreaction, Barclays' Field Says
Posted
December 20, 2024
Views
10,430
Likes
122
Comments
24
Engagement
December 20, 2024
10,430
122
24
1.40%
Every word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
See what was published immediately before and after this episode.
4:35Now PlayingEmily Field, Barclays’ head of European pharmaceutical research, reacts to the selloff in Novo Nordisk's shares after its experimental obesity shot CagriSema failed to meet expectations. She speaks on "Bloomberg Open Interest."
Sign up for the Prognosis newsletter to get the latest in health, medicine and science and what it means for you from Bloomberg’s global team of health reporters
--------
More on Bloomberg Television and Markets
Like this video? Subscribe and turn on notifications so you don't miss any videos from Bloomberg Markets & Finance
Visit for business news & analysis, uptotheminute market data, features, profiles and more.
Connect with Bloomberg Television on:
Connect with Bloomberg Business on:
More from Bloomberg:
Bloomberg Radio
Bloomberg Surveillance
Bloomberg Politics
Bloomberg Originals
Watch more on YouTube:
Bloomberg Technology
Bloomberg Originals
Bloomberg Quicktake
Bloomberg Espanol
Bloomberg Podcasts
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.
